Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
Business Wire India New Phase II data show evobrutinib sustained low annualized relapse rates (ARRs) and had no new safety signals at 2.5 years – the longest follow-up of any…